Kenealy Helen, Holdaway Ian, Grey Andrew
Department of Endocrinology, Auckland City Hospital, Park Road, Grafton, Auckland, New Zealand.
Eur J Intern Med. 2008 Nov;19(7):516-9. doi: 10.1016/j.ejim.2008.01.011. Epub 2008 Mar 10.
Oncogenic osteomalacia (OOM) is a rare but curable cause of metabolic bone disease. We report 9 patients with OOM, including 2 patients with occult nasal sinus tumours and 1 in whom a progressive increase in the post-operative FGF23 level heralded the development of metastatic pulmonary disease. The median duration of symptoms before definitive surgical treatment was 6 years, and in one patient was more than 10 years. This series demonstrates that careful imaging of the nasal sinuses should be part of the work-up of cases of oncogenic osteomalacia, that serum FGF23 can be helpful in both diagnosis and monitoring treatment outcomes, and emphasizes that serum phosphate should be measured in patients with metabolic bone disease and/or unexplained musculoskeletal symptoms.
致癌性骨软化症(OOM)是一种罕见但可治愈的代谢性骨病病因。我们报告了9例OOM患者,其中包括2例隐匿性鼻窦肿瘤患者和1例术后FGF23水平逐渐升高预示着转移性肺病发生的患者。明确手术治疗前症状的中位持续时间为6年,其中1例患者超过10年。该系列研究表明,对鼻窦进行仔细的影像学检查应作为致癌性骨软化症病例检查的一部分,血清FGF23有助于诊断和监测治疗结果,并强调对于患有代谢性骨病和/或不明原因肌肉骨骼症状的患者应检测血清磷酸盐。